Talazoparib in Patients with Advanced Breast Cancer and a Germline <i>BRCA</i> Mutation

20182,086 citationsJournal Articlegreen Open Access

Authors

Jennifer K. Litton · The University of Texas MD Anderson Cancer Center

Hope S. Rugo · University of California, San Francisco

Johannes Ettl · Klinikum rechts der Isar

Sara A. Hurvitz · University of California, Los Angeles

Anthony Gonçalvès · Institut Paoli-Calmettes

Kyung-Hun Lee · Seoul National University Hospital

Louis Fehrenbacher

Abstract

Among patients with advanced breast cancer and a germline BRCA1/2 mutation, single-agent talazoparib provided a significant benefit over standard chemotherapy with respect to progression-free survival. Patient-reported outcomes were superior with talazoparib. (Funded by Medivation [Pfizer]; EMBRACA ClinicalTrials.gov number, NCT01945775 .).

Topics & Keywords

PARP inhibition in cancer therapy BRCA gene mutations in cancer DNA Repair Mechanisms

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 379, Issue 8, pp. 753-763

DOI: 10.1056/nejmoa1802905

Field-Weighted Citation Impact: 77.52